Glycomimetics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.48% of Crescent Biopharma, Inc. common stock as of March 31, 2026.
FMR LLC and Abigail P. Johnson have disclosed a 15.0% beneficial ownership stake in Crescent Biopharma Inc. common stock as of December 31, 2025.
Forbion Growth III PA B.V. and affiliated entities have reported a 6.1% beneficial ownership stake in Crescent Biopharma, Inc. following a recent private placement.
1Globe Capital LLC and Chairman Jiaqiang Li have reported a 10.3% beneficial ownership stake in Crescent Biopharma, Inc. ordinary shares.
Tang Capital Management and affiliates report a 5.04% beneficial ownership in Crescent Biopharma, Inc., holding 700,000 ordinary shares.
1Globe Capital LLC and its Chairman, Jiaqiang Li, have disclosed a passive beneficial ownership of 6.45% in Crescent Biopharma, Inc., totaling 896,712 ordinary shares.
A group of investment entities led by Biotechnology Value Fund L.P. reported a 9.99% beneficial ownership stake in Crescent Biopharma, Inc. as of June 30, 2025.
Logos Global Management LP and related entities have filed an amended Schedule 13G, disclosing a 4.1% passive beneficial ownership stake in Crescent Biopharma, Inc. as of June 30, 2025.
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a beneficial ownership of 10.2% of Crescent Biopharma Inc.'s common stock as of June 30, 2025.
Venrock Healthcare Capital Partners and affiliated entities have disclosed a passive 9.9% beneficial ownership stake in Crescent Biopharma, Inc., primarily through ordinary shares and pre-funded warrants.
RA Capital Management and its affiliated entities have filed an amended Schedule 13G, reporting zero beneficial ownership in GlycoMimetics, Inc. as of December 31, 2024.